REZZAYO
Peakrezafungin
NDAINTRAVENOUSPOWDERPriority Review
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZZAYO (rezafungin) is an intravenous echinocandin antifungal approved in March 2023 for invasive candidiasis and candidemia. It works by inhibiting fungal cell wall synthesis, similar to other echinocandins, and is administered as an IV powder formulation. The drug targets hospitalized patients with serious Candida infections.
$0.061MPart D
Peak12.2 years to LOEEarly-stage product in peak lifecycle phase with minimal current market penetration; early commercial team building and market development roles are primary focus areas.
Mechanism of Action
Pharmacologic Class:
Echinocandin Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety and Pharmacokinetics of Rezafungin
Started Dec 2019
14 enrolled
Fungal Infection
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Started Oct 2018
199 enrolled
CandidemiaMycosesFungal Infection+1 more
Career Relevance
REZZAYO offers early-stage commercial growth opportunity with modest current market uptake ($61K in 2023 claims) in a competitive established category. Career roles are concentrated in commercial launch and hospital formulary positioning; long patent runway (12+ years) provides stability but limited research/development opportunity.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.